Arctic Bioscience – Mandatory notification of trade


Reference is made to the stock exchange release regarding approval of share capital increase, published 21st April 2023.

Ronja Capital II AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today subscribed 943 833 shares, at a subscription price of NOK 17,27 per share. As part of the share capital increase process this subscription and capital increase will be registered in the Norwegian Register of Business Enterprises.

Following the subscription and registration, Ronja Capital II AS will hold 3 087 999 shares in Arctic Bioscience, corresponding to 12,17 % of the total number of shares.

Member of the Board of Directors, Tore A. Tønseth, is Investment Director at Ronja Capital II AS.

Please refer to the attached notification of trading for further details. 

This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

For more information, please contact:

Jone R. Slinning


Phone: +47 948 75 469


About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.

The company is developing HRO350 – a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.

Documents & Links

20230424 – Appendix 3 – Notifying Transactions – Ronja Capital II AS